๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 2847 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Sep 2026, 03:15 UTC
2847
Studies in scope
industry-sponsored, all four open statuses
1382
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2004 Manchester 672 Birmingham 470 Glasgow 437 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Merck Sharp & Dohme LLC98 Hoffmann-La Roche80 Janssen Research & Development, LLC73 Novartis Pharmaceuticals72
Site city
London2004 Manchester672 Birmingham470 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
2004 of 2847 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
NCT03301506Primary Biliary Cirrhosis
Gilead Sciences
Phase 3
340
Birmingham, Hull, London, Newcastle upon Tyne, Nottingham, Plymouth, Portsmouth
2017-12-12
Active, closed
A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
NCT03332797Breast Cancer
Genentech, Inc.
Phase 1
181
London, Suttton
2017-11-24
Active, closed
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
NCT03336333Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
BeiGene
Phase 3
590
Birmingham, Bournemouth, Cambridge, Canterbury, Greater Manchester, Leeds, London, Maidstone
2017-10-31
Active, closed
Endurant CHevAr New Indication Trial: ENCHANT
NCT03320252AAA - Abdominal Aortic Aneurysm
Medtronic Cardiovascular
Observational
150
London, Manchester
2017-10-26
Active, closed
A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis
NCT03218488Psoriasis
Janssen-Cilag International NV
Observational
135
Cardiff, London, Salford
2017-10-25
Recruiting
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
NCT03373968Duchenne Muscular Dystrophy
Italfarmaco
Phase 2/3
206
Liverpool, Gobowen, London, Newcastle upon Tyne
2017-10-24
Active, closed
A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa
NCT03019406Glycogen Storage Disease Type II-Pompe's Disease
Genzyme, a Sanofi Company
Phase 2
22
London, Manchester
2017-10-12
Recruiting
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer
Apollomics Inc.
Phase 2
497
London, Manchester, Surrey Quays
2017-09-27
Active, closed
H1 Hip Resurfacing Arthroplasty
NCT03326804Hip Osteoarthritis, Hip Necrosis, Hip Dysplasia
Embody Orthopaedic Limited
Observational
250
London
2017-09-26
Active, closed
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
NCT03767348Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma
Replimune, Inc.
Phase 2
340
Leeds, Oxford, Glasgow, Bebington, London, Southampton
2017-09-20
Active, closed
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
NCT03148418Cancer
Hoffmann-La Roche
Phase 3
382
London, Manchester, Metropolitan Borough of Wirral, Nottingham, Surrey
2017-09-20
Active, closed
Global Fenestrated Anaconda Clinical STudy
NCT03180996Abdominal Aortic Aneurysm
Vascutek Ltd.
Observational
160
Newcastle upon Tyne, Camberley, London
2017-09-11
Active, closed
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03170960Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
Exelixis
Phase 1
914
Middlesex, Preston, Cardiff, London
2017-09-05
Active, closed
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
NCT02962414Tuberous Sclerosis Complex
Novartis Pharmaceuticals
Phase 3
206
Birmingham, Buckinghamshire, Cambridge, Liverpool, London, Sheffield
2017-08-23
Active, closed
Personalized Therapy Study - Attain Stability Quad Post-Approval Study
NCT04024943Heart Failure
Medtronic
Observational
1,092
Birmingham, Blackpool, Liverpool, London, Manchester, Middlesbrough, Sheffield
2017-08-21
Recruiting
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
NCT03016819Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma
Advenchen Laboratories, LLC
Phase 3
325
London
2017-08-15
Active, closed
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
NCT03313778Solid Tumors
ModernaTX, Inc.
Phase 1
161
Dundee, Sutton, London
2017-08-14
Active, closed
Study of E7386 in Participants With Selected Advanced Neoplasms
NCT03264664Advanced Neoplasms
Eisai Inc.
Phase 1
60
Glasgow, Manchester, Sutton, London
2017-07-27
Active, closed
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
NCT02952508Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Cellectar Biosciences, Inc.
Phase 2
120
London
2017-07-26
Active, closed
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
NCT03155997Breast Cancer
Eli Lilly and Company
Phase 3
5,637
Truro, Chelmsford, London, Northwood, Blackpool, Preston, Boston, Central Middlesbrough
2017-07-12
Active, closed
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Swedish Orphan Biovitrum
Phase 3
407
Sheffield, Glasgow, London, Gloucester, Oxford
2017-06-26
Active, closed
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
NCT03164616Non Small Cell Lung Cancer NSCLC
AstraZeneca
Phase 3
1,186
Leicester, London, Manchester
2017-06-01
Active, closed
REDUCE LAP-HF TRIAL II
NCT03088033Heart Failure
Corvia Medical
Not applicable
608
Glasgow, London
2017-06-01
Active, closed
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
NCT03229200Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease
Pharmacyclics Switzerland GmbH
Phase 4
297
Cardiff, Leeds, London, Manchester
2017-05-22
Active, closed
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
NCT03157128Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
Eli Lilly and Company
Phase 1/2
857
London
2017-05-02
Recruiting
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
NCT03067051Recurrent Prostate Cancer
SpectraCure AB
Phase 1/2
66
London
2017-03-21
Recruiting
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
NCT03093116Locally Advanced Solid Tumors, Metastatic Solid Tumors
Turning Point Therapeutics, Inc.
Phase 1/2
500
London, Manchester, Sutton
2017-03-07
Active, closed
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
NCT03069469Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor
Deciphera Pharmaceuticals, LLC
Phase 1/2
120
London
2017-02-16
Active, closed
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
NCT02970318Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 3
310
Birmingham, Cambridge, Canterbury, Leicester, London, Maidstone, Manchester, Southampton
2017-02-02
Active, closed
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
NCT03049189Neuroendocrine Tumors
ITM Solucin GmbH
Phase 3
324
London, Manchester
2017-02-02
Active, closed
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
NCT03006068Ulcerative Colitis (UC)
AbbVie
Phase 3
950
Bath, Exeter, Basingstoke, London, Glasgow, Birmingham, Huddersfield
2017-01-31
Active, closed
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
NCT02546661Muscle Invasive Bladder Cancer
AstraZeneca
Phase 1
117
Glasgow, London, Manchester, Southampton
2016-12-28
Active, closed
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
NCT02960022Prostate Cancer
Astellas Pharma Global Development, Inc.
Phase 2
900
Bebington, Belfast, Bristol, Cambridge, Cardiff, Glasgow, London, Manchester
2016-12-22
Active, closed
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
NCT03006172Breast Cancer, Solid Tumor
Genentech, Inc.
Phase 1
200
Surrey, London
2016-12-13
Recruiting
Neurovascular Product Surveillance Registry
NCT02988128Intracranial Aneurysm, Stroke, Ischemic
Medtronic Neurovascular Clinical Affairs
Observational
4,000
Birmingham, Edinburgh, London, Romford, Stoke-on-Trent
2016-12
Recruiting
Fosfomycin I.v. for Treatment of Severely Infected Patients
NCT02979951Bacterial Infections, Bone Diseases, Infectious, Osteomyelitis, Central Nervous System Bacterial Infections
Infectopharm Arzneimittel GmbH
Observational
1,000
Bolton, Cottingham, Dundee, Glasgow, Kilmarnock, London
2016-12
Active, closed
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
NCT02908906Neoplasms
Janssen Research & Development, LLC
Phase 1/2
234
Glasgow, London, Manchester, Newcastle upon Tyne
2016-11-21
Active, closed
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
NCT02938520HIV Infections
ViiV Healthcare
Phase 3
631
Birmingham, Coventry, Leeds Yorkshire, London
2016-10-27
Active, closed
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
NCT02811861Renal Cell Carcinoma
Eisai Inc.
Phase 3
1,069
Bournemouth, Cardiff, Edinburgh, Glasgow, Leeds, London, Manchester
2016-10-13
Active, closed
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
NCT02655016Ovarian Neoplasms
Tesaro, Inc.
Phase 3
733
Blackburn, Edinburgh, Exeter, Glasgow, London, Portsmouth, Sheffield, Truro
2016-07-11
Active, closed
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
NCT02716116Carcinoma, Non-Small-Cell Lung
Takeda
Phase 1/2
334
London
2016-06-16
Active, closed
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
NCT02677922Leukemia, Myeloid, Acute
Celgene
Phase 1/2
130
Birmingham, Headington, London, Sutton (Surrey)
2016-06-03
Active, closed
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
NCT02711553Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer
Eli Lilly and Company
Phase 2
309
London, Manchester, Acton, Bebbington, Sutton
2016-05-19
Active, closed
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
NCT02650401Solid Tumors, CNS Tumors
Hoffmann-La Roche
Phase 1/2
69
London, Newcastle upon Tyne
2016-05-03
Active, closed
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
NCT02734004Ovarian, Breast, SCLC, Gastric Cancers
AstraZeneca
Phase 1/2
264
Cambridge, Dundee, Glasgow, Greater London, London, Manchester, Newcastle upon Tyne, Sutton
2016-03-17
Active, closed
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284Neoplasms
Tesaro, Inc.
Phase 1
729
Newcastle upon Tyne, Aberdeen, London, Manchester, Oxford, Sutton
2016-03-07
Recruiting
Verciseโ„ข DBS Dystonia Prospective Study
NCT02686125Dystonia
Boston Scientific Corporation
Observational
300
Bristol, Glasgow, London, Newcastle upon Tyne
2016-03-07
Active, closed
REDUCER-I: An Observational Study of the Neovasc Reducerโ„ข System
NCT02710435Angina Pectoris, Angina Pectoris, Stable, Chronic Stable Angina
Shockwave Medical, Inc.
Observational
400
Bradford, Edinburgh, London
2016-03
Active, closed
A Study of the ReCor Medical Paradise System in Clinical Hypertension
NCT02649426Hypertension, Vascular Diseases
ReCor Medical, Inc.
Not applicable
282
Bournemouth, London, Basildon, Exeter, Hastings, Nottingham
2016-03
Active, closed
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
NCT02671435Advanced Solid Tumors
MedImmune LLC
Phase 1/2
383
London, Sutton
2016-02-22
Active, closed
A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)
NCT02724228Achondroplasia
BioMarin Pharmaceutical
Phase 2
30
London
2016-01-26
Active, closed
Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product
NCT02698579Cerebral Adrenoleukodystrophy (CALD), Adrenoleukodystrophy (ALD), X-Linked Adrenoleukodystrophy (X-ALD)
Genetix Biotherapeutics Inc.
Observational
64
London
2016-01-22
Active, closed
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
NCT02629159Rheumatoid Arthritis
AbbVie
Phase 3
1,629
London, Portsmouth, Warrington
2015-12-01
Active, closed
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
NCT02489318Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Carlisle, Dundee, Glasgow, London, Newcastle upon Tyne, Oxford, Plymouth, Scunthorpe
2015-11-27
Active, closed
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
NCT02568267Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms
Hoffmann-La Roche
Phase 2
534
Cambridge, London, Manchester
2015-11-19
Active, closed
On-X Aortic Prosthetic Heart Valve Low Dose Warfarin Post Approval Clinical Registry Study
NCT02677974Thrombotic and Bleeding Events
On-X Life Technologies, Inc.
Observational
510
Blackpool, Hull, London, Oxford, Southampton
2015-11-10
Active, closed
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
NCT02542293Non Small Cell Lung Carcinoma NSCLC
AstraZeneca
Phase 3
953
Guildford, London, Manchester, Metropolitan Borough of Wirral, Nottingham, Taunton, Wolverhampton
2015-11-03
Active, closed
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
NCT02516241Urothelial Cancer
AstraZeneca
Phase 3
1,126
Cambridge, Cardiff, Glasgow, Leeds, London, Manchester, Metropolitan Borough of Wirral, Sheffield
2015-11-02
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,400
Birmingham, London
2015-11-02
Active, closed
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
NCT02486718Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3
1,280
Birmingham, Colchester, Essex, London
2015-10-31
Active, closed
Study to Assess the Long-term Safety of Dupilumab Administered in Participants โ‰ฅ6 Months to <18 Years of Age With Atopic Dermatitis (AD)
NCT02612454Atopic Dermatitis
Regeneron Pharmaceuticals
Phase 3
880
London, Manchester, Sheffield
2015-10-15
Active, closed
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
NCT02503423Solid Tumors, Lymphoma
Taiho Oncology, Inc.
Phase 1/2
253
Leicester, Southampton, Oxford, Sutton, Birmingham, Glasgow, London, Manchester
2015-07-14
Active, closed
Micra Transcatheter Pacing System Post-Approval Registry
NCT02536118Bradycardia
Medtronic
Observational
3,100
Birmingham, Bristol, Leeds, Leicester, Liverpool, London, Manchester, Middlesbrough
2015-07
Active, closed
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naรฏve CLL
NCT02475681Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 3
535
Bournemouth, Cambridge, Leeds, Leicester, London, Plymouth, Southampton, Truro
2015-06-26
Active, closed
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
NCT02411448Metastatic Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 3
545
London, Chelsea, Nottingham
2015-05-06
Active, closed
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
NCT02365597Urothelial Cancer
Janssen Research & Development, LLC
Phase 2
239
Blackburn, Dundee, Essex, London, Metropolitan Borough of Wirral, Plymouth, Sutton
2015-04-22
Active, closed
Transcatheter Mitral Valve Replacement System (TMVR) Pilot Study and The Early Feasibility Study of the TMVR Transseptal System
NCT02322840Mitral Valve Insufficiency
Medtronic Cardiovascular
Not applicable
128
Brighton, Leeds, London
2015-04
Recruiting
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
NCT02332668Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma
Merck Sharp & Dohme LLC
Phase 1/2
370
London
2015-03-19
Active, closed
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
NCT02362503HIV Infections
ViiV Healthcare
Phase 3
371
Bournemouth, Leicester, London
2015-02-23
By invitation
Registry of Patients With Hypophosphatasia
NCT02306720Hypophosphatasia (HPP)
Alexion Pharmaceuticals, Inc.
Observational
1,571
Bristol, London, Leicester, Stanmore, Oxford, Sheffield, Newcastle upon Tyne, Birmingham
2015-01-20
Active, closed
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
NCT02912949Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
Partner Therapeutics, Inc.
Phase 2
250
London
2015-01
Active, closed
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Pfizer
Phase 3
1,068
Glasgow, Wonford, London, Sutton, Birmingham, Bristol
2014-12-17
Active, closed
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT02257736Prostatic Neoplasms
Aragon Pharmaceuticals, Inc.
Phase 3
982
Ayr, Belfast, Birmingham, Edinburgh, Glasgow, London, Manchester, Metropolitan Borough of Wirral
2014-11-26
Active, closed
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02227251Diffuse Large B-cell Lymphoma
Karyopharm Therapeutics Inc
Phase 2
244
Gloucester, Southampton, Sutton, Harrow, Leeds, Cambridge, Liverpool, London
2014-11
Active, closed
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
NCT02264678Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
AstraZeneca
Phase 1
358
Bristol, Cambridge, Coventry, London, Manchester, Oxford, Sutton, Withington
2014-10-31
Active, closed
An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenstrรถm Macroglobulinemia
NCT02180724Waldenstrรถm Macroglobulinemia (WM)
Acerta Pharma BV
Phase 2
107
Bournemouth, Leeds, Leicester, London, Oxford, Plymouth, Southampton
2014-09-11
Active, closed
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
NCT02130362Crohn's Disease
AbbVie
Observational
1,446
Derby, Sheffield, London, Southampton, Glasgow, Carshalton, Aberdeen, Birmingham
2014-08-28
Active, closed
PERIGON Pivotal Trial
NCT02088554Aortic Stenosis
Medtronic Cardiac Surgery
Not applicable
1,312
London
2014-05-12
Recruiting
Registry of Deep Brain Stimulation With the VERCISEโ„ข System: Vercise DBS Registry
NCT02071134Parkinson's Disease
Boston Scientific Corporation
Observational
1,500
Bristol, Glasgow, Liverpool, London, Newcastle, Oxford
2014-03-04
Active, closed
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
NCT02029443Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Prolymphocytic Leukemia
Acerta Pharma BV
Phase 1/2
306
Leeds, London, Oxford
2014-01-30
Active, closed
Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV
NCT02016924Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Gilead Sciences
Phase 2/3
133
London
2014-01-16
Active, closed
Long-term Follow-up of Subjects With Transfusion-Dependent ฮฒ-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy
NCT02633943Transfusion-dependent Beta-Thalassemia
Genetix Biotherapeutics Inc.
Observational
66
London
2014-01
Active, closed
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
NCT01946204Prostatic Neoplasms
Aragon Pharmaceuticals, Inc.
Phase 3
1,207
Blackburn, Cambridge, Cardiff, Dundee, Glasgow, Guildford, Leeds, London
2013-10-14
Active, closed
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
NCT01933932Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
AstraZeneca
Phase 3
510
Aberdeen, London, Manchester, Nottingham, Sutton, Wolverhampton
2013-09-25
Recruiting
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Janssen Research & Development, LLC
Phase 3
700
Birmingham, Bournemouth, Colchester, Glasgow, Leeds, Leicester, London, Manchester
2013-09-09
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
AstraZeneca
Phase 3
327
Birmingham, Cambridge, Coventry, Edinburgh, London, Manchester, Sutton
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
AstraZeneca
Phase 3
450
Birmingham, Cambridge, Coventry, Edinburgh, London, Sutton
2013-08-26
Active, closed
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
NCT01892722Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
240
West Midlands, Edinburgh, London
2013-07-26
Recruiting
Lysosomal Acid Lipase (LAL) Deficiency Registry
NCT01633489Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease, Wolman Disease, Acid Cholesteryl Ester Hydrolase Deficiency, Type 2
Alexion Pharmaceuticals, Inc.
Observational
300
Cambridge, London, Manchester, Salford, Birmingham
2013-05-30
Active, closed
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
NCT01843374Unresectable Pleural or Peritoneal Malignant Mesothelioma
MedImmune LLC
Phase 2
571
Leeds, Leicester, London, Maidstone, Manchester, Metropolitan Borough of Wirral, Plymouth, Southampton
2013-05-17
Active, closed
A Long-Term Registry of Humiraยฎ (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
NCT01848561Ulcerative Colitis (UC)
AbbVie
Observational
8,250
Warrington, Darlington, Plymouth, Poole, Hull, London, Basingstoke, Glasgow
2013-04-29
Recruiting
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183Atypical Hemolytic-Uremic Syndrome
Alexion Pharmaceuticals, Inc.
Observational
3,000
Cardiff, Exeter, London, Manchester, Newcastle, Southampton, Wales
2013-03-18
Recruiting
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
NCT01719055Pain
Boston Scientific Corporation
Observational
4,800
Basildon, Bristol, Leeds, London, Middlesbrough, Stanmore
2012-11-19
Recruiting
Patient Retrospective Outcomes (PRO)
NCT01550575Chronic Pain
Boston Scientific Corporation
Observational
15,000
Basildon, Bristol, Exeter, Leeds, London, Middlesbrough
2012-04-03
Active, closed
Safety and Efficacy Study of the Medtronic CoreValveยฎ System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).
NCT01586910Severe Aortic Stenosis
Medtronic Cardiovascular
Not applicable
1,746
Leeds, Leicester, London
2012-04
Active, closed
Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)
NCT01385176Heart Failure, Congestive Heart Failure
Boston Scientific Corporation
Not applicable
118
Bristol, Liverpool, London
2011-09-21
Recruiting
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlexยฎ in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
NCT00903110IGF1 Deficiency
Esteve Pharmaceuticals, S.A.
Observational
500
Belfast, Birmingham, Leeds, London, Manchester
2008-12-09
Active, closed
Phase I Comparative Bioavailability Study
NCT00777582Solid Tumors
AstraZeneca
Phase 1
197
Edinburgh, London, Manchester, Newcastle upon Tyne, Northwood, Oxford, Sutton
2008-10-27
Active, closed
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
NCT00781612Neoplasm Metastasis
Genentech, Inc.
Phase 2
378
Dundee, Edinburgh, Grimsby, Lancaster, London, Manchester, Middlesex, Nottingham
2008-10-16
Active, closed
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
NCT00750841Solid Tumors
AstraZeneca
Phase 1
64
Dundee, Glasgow, London
2008-09-09
Rows per page Showing 1901–2000 of 2004
Previous 18 19 20 21 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-uk/city/london?page=20

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.